We suggest that LB polymorphism reflects a wide array of barrier adaptations to environmental challenges, rather than just a defective barrier function, based on observations on a) LB morphology in inherited skin disorders of lipid metabolism (Refsum disease, Chanarin-Dorfman syndrome) characterized by deficiency of lamellar lipids and accumulation of toxic metabolites; b) Psoriasis (with a high expression of Psoriasin antimicrobial peptide within lesions) and c) the Pitohui, a toxic bird where diet-derived toxin is eliminated via the LB secretory system that creates a chemical defense system.
We also report the strong correlation in the breast epithelial SAGE libraries between the expression of S100A7 and genes reported as being up-regulated in DCIS, as well as in the inflammatory skin disorder, psoriasis; including RGS5, UPK1A, TMPRSS3, S100A9, p53, SCCA1, SCCA2 and KRT17.
Psoriasin is a small calcium-binding protein first found in psoriatic lesions and also up-regulated in other inflammatory skin diseases and cancer tissues.
Expression of the cytokeratin 1 (K1) gene was, in contrast, high in normal skin and decreased in the transition from uninvolved skin to psoriatic plaque, Examination of mRNA levels of CRABP II and psoriasin in other hyperproliferative and inflammatory skin diseases showed high expression of psoriasin, and in some cases also of CRABP II, in atopic dermatitis, mycosis fungoides, Darier's disease and inflammatory lichen sclerosus et atrophicus.